HHS Backs DEA Plan to Place Synthetic Kratom Extract on Schedule I
Federal alignment between HHS and DEA on 7-hydroxymitragynine scheduling moves the substance closer to the most restrictive drug control category, a step that would affect an estimated number of...
The Department of Health and Human Services formally endorsed the Drug Enforcement Administration's proposal to classify 7-hydroxymitragynine (7-OH), a synthetic extract derived from the kratom plant, as a Schedule I controlled substance, according to The Hill, which reported the development on Friday, October 9, 2026.
Schedule I is the most restrictive classification under the Controlled Substances Act, reserved for substances the federal government determines have no currently accepted medical use and a high potential for abuse. Other Schedule I substances include heroin and LSD, per the DEA's published scheduling criteria.
The DEA announced in July 2026 its intent to temporarily schedule 7-OH and related synthetic compounds. That announcement initiated a formal rulemaking process. HHS's endorsement, added Friday, represents the public health agency's independent scientific and medical recommendation, a step required under 21 U.S.C. Section 811 before the DEA can finalize a scheduling action.
The compound has been marketed colloquially as a "gas station opioid," a reference to its widespread retail availability in convenience stores, smoke shops, and online platforms prior to any federal scheduling. Kratom itself, derived from the Mitragyna speciosa plant native to Southeast Asia, remains unscheduled at the federal level as of the date of this report. The DEA attempted to schedule kratom's primary alkaloids in 2016 but withdrew that proposal following public comment. The current action targets only the synthetic extract 7-OH and related synthetic compounds, not the raw plant or its naturally occurring alkaloids.
The distinction between naturally occurring mitragynine and synthetic 7-OH is central to the regulatory argument. Industry groups representing kratom vendors have previously contended that naturally derived kratom products should not be conflated with synthetically processed extracts. What specific products would be captured under the proposed scheduling language is not fully detailed in the public DEA filing reviewed for this report. The complete list of "related compounds" targeted alongside 7-OH has not been published in a form that specifies every affected substance by chemical name in the materials available as of October 9, 2026.
Temporary scheduling under the Controlled Substances Act allows the DEA to place a substance on Schedule I for up to three years, with a possible one-year extension, while a full scientific review is completed. A temporary order takes effect upon publication in the Federal Register and does not require congressional approval.
Congress has separately considered kratom-related legislation in recent sessions. The Federal Analogue Act, already in existing law, provides a mechanism to treat substances chemically similar to Schedule I or II drugs as controlled if intended for human consumption, though its application to kratom-derived compounds has not been adjudicated in a controlling federal court decision as of this writing.
The American Kratom Association, a trade and advocacy organization that lobbies on behalf of kratom consumers and vendors, has filed comments opposing prior DEA scheduling efforts. Whether it submitted formal comments on the current 7-OH proposal is not confirmed in the public docket materials reviewed for this report. The DEA's public comment docket number for the July 2026 proposed temporary order would contain that information.
The economic scope of the synthetic kratom extract market has not been independently audited by a federal agency in any document located for this report. Total retail sales figures, the number of affected businesses, and the number of consumers who use 7-OH products are not established in the current public record.
What remains unknown includes the precise effective date of any final temporary scheduling order, the full chemical list of "related compounds" targeted alongside 7-OH, and whether any manufacturer or vendor has filed a legal challenge to the proposed action. The Federal Register publication of the final temporary order would establish the effective date and the complete list of scheduled compounds. Court filings in the relevant federal district, if any challenge is filed, would reveal whether any party seeks to enjoin the scheduling action.